Immune reconstitution during the first year of antiretroviral therapy of HIV-1-infected adults in rural Burkina Faso

Open AIDS Journal

Volumn 6, Issue 1, 2012, Pages 16-25

  Tiba, Fabrice ^a   Nauwelaers, Frans ^b   Traoré, Siaka ^c   Coulibaly, Boubacar ^c   Ouedraogo, Thierry ^c   Compaoré, Adama ^c   Kräusslich, Hans Georg ^a   Böhler, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BD Biosciences ^*  (Belgium)

^c CENTRE DE RECHERCHE EN SANTÉ DE NOUNA   (Burkina Faso)

Author keywords

Africa; CD95; HAART; HIV; T cell activation

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; FAS ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ANTIGEN EXPRESSION; ARTICLE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VOMITING;

EID: 84859480852     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613601206010016     Document Type: Article

References (27)

1. Tebit DM, Ganamé J, Sathiandee K, Nagabila Y, Coulibaly B, Krausslich HG. Diversity of HIV in rural Burkina Faso. J Acquir Immune Defic Syndr 2006; 43: 144-52.
2. Klose N, Coulibaly B, Tebit DM, et al. Immunohematological reference values for healthy adults in Burkina Faso. Clin Vaccine Immunol 2007; 14: 782-4.
3. Böhler T, von Au M, Klose N, et al. Evaluation of a simplified dual-platform flow cytometric method for measurement of lymphocyte subsets and T-cell maturation phenotypes in the population of Nouna, Burkina Faso. Clin Vaccine Immunol 2007; 14: 775-81.
4. Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev 2006; 127: 274-81.
5. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
6. Böhler T, Wintergerst U, Linde R, Belohradsky BH, Debatin KM. CD95 (APO-1/Fas) expression on naive CD4(+) T cells increases with disease progression in HIV-infected children and adolescents: effect of highly active antiretroviral therapy (HAART). Pediatr Res 2001; 49: 101-10.
7. Ondoa P, Koblavi-Deme S, Borget MY, Nolan ML, Nkengasong JN, Kestens L. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Cote d'Ivoire. Clin Exp Immunol 2005; 140: 138-48.
8. Tuaillon E, Al Tabaa Y, Baillat V, et al. Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count. Cytometry B Clin Cytom 2009; 76: 249-60.
9. Gilson RJ, Man SL, Copas A, et al. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2009; 11: 152-60.
10. Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials 2002; 3: 186-94.
11. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4: 208-14.
12. Carcelain G, Debre P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001; 13: 483-8.
13. Glencross DK, Janossy G, Coetzee LM, et al. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom 2008; 74 (Suppl 1): S131-40.
14. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48: 350-61.
15. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4:9.
16. Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE. Thymic-independent T cell regeneration occurs via antigendriven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996; 156: 4609-16.
17. Di Mascio M, Sereti I, Matthews LT, et al. Naive T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion. J Virol 2006; 80: 2665-74.
18. Nielsen SD, Sorensen TU, Ersboll AK, et al. Decrease in immune activation in HIV-infected patients treated with highly active antiretroviral therapy correlates with the function of hematopoietic progenitor cells and the number of naive CD4+ cells. Scand J Infect Dis 2000; 32: 597-603.
19. Amendola A, Poccia F, Martini F, et al. Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group. Clin Exp Immunol 2000; 120: 324-32.
20. Beran O, Holub M, Spala J, Kalanin J, Stankova M. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART. Acta Virol 2003; 47: 121-4.
21. Koblavi-Deme S, Maran M, Kabran N, et al. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy. AIDS 2003; 17 (Suppl 3): S17-22.
22. Böhler T, Bäumler C, Herr I, Groll A, Kurz M, Debatin KM. Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents. Pediatr Infect Dis J 1997; 16:754-9.
23. Aries SP, Schaaf B, Muller C, Dennin RH, Dalhoff K. Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression. J Mol Med 1995; 73: 591-3.
24. Collenberg E, Ouedraogo T, Ganamé J, et al. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. J Med Virol 2006; 78: 683-92.
25. Miles DJ, van der Sande M, Jeffries D, et al. Cytomegalovirus infection in Gambian infants leads to profound CD8 T-cell differentiation. J Virol 2007; 81: 5766-76.
26. Onlamoon N, Tabprasit S, Suwanagool S, Louisirirotchanakul S, Ansari AA, Pattanapanyasat K. Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand. Virology 2005; 341: 238-47.
27. Ondoa P, Dieye TN, Vereecken C, et al. Evaluation of HIV-1 p24 antigenemia and level of CD8+CD38+ T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar, Senegal. J Acquir Immune Defic Syndr 2006; 41: 416-24.